79 related articles for article (PubMed ID: 17352243)
1. Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Thomas H
Anticancer Res; 2007; 27(1A):273-8. PubMed ID: 17352243
[TBL] [Abstract][Full Text] [Related]
2. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
3. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
4. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM
Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
6. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Pennati M; Campbell AJ; Curto M; Binda M; Cheng Y; Wang LZ; Curtin N; Golding BT; Griffin RJ; Hardcastle IR; Henderson A; Zaffaroni N; Newell DR
Mol Cancer Ther; 2005 Sep; 4(9):1328-37. PubMed ID: 16170024
[TBL] [Abstract][Full Text] [Related]
8. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
9. Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.
Eskander RN; Randall LM; Sakai T; Guo Y; Hoang B; Zi X
J Obstet Gynaecol Res; 2012 Aug; 38(8):1086-94. PubMed ID: 22540374
[TBL] [Abstract][Full Text] [Related]
10. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Ribas J; Boix J; Meijer L
Exp Cell Res; 2006 Jul; 312(12):2394-400. PubMed ID: 16765943
[TBL] [Abstract][Full Text] [Related]
11. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
12. Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines.
Gu J; Yamamoto H; Lu X; Ngan CY; Tsujino T; Konishi K; Takemasa I; Ikeda M; Nagata H; Hashimoto S; Matsuzaki T; Sekimoto M; Takagi A; Monden M
Digestion; 2006; 74(1):19-27. PubMed ID: 16988507
[TBL] [Abstract][Full Text] [Related]
13. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
15. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Hu H; Li GX; Wang L; Watts J; Combs GF; Lü J
Clin Cancer Res; 2008 Feb; 14(4):1150-8. PubMed ID: 18281549
[TBL] [Abstract][Full Text] [Related]
16. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.
Lambert LA; Qiao N; Hunt KK; Lambert DH; Mills GB; Meijer L; Keyomarsi K
Cancer Res; 2008 Oct; 68(19):7966-74. PubMed ID: 18829554
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F
Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
20. The tricyclic antidepressant amitriptyline is cytotoxic to HTB114 human leiomyosarcoma and induces p75(NTR)-dependent apoptosis.
Pula G; Pistilli A; Montagnoli C; Stabile AM; Rambotti MG; Rende M
Anticancer Drugs; 2013 Oct; 24(9):899-910. PubMed ID: 23872911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]